BACK

 INFORMATION ON THE GOVERNANCE OF LFB SA: AMENDMENT OF STATUTES FOR COMPLIANCE PURPOSE

The General Meeting of November 24th, 2016 amended the Company’s statutes to implement the provisions of Order #2014-948 of August 20th, 2014* on the governance and equity operations of Stateowned companies (hereafter “the Order”).

Pursuant to the Order, LFB SA is now administrated by a Board of Directors with three to 18 members, appointed at the General Meeting, as the case may be on the proposal of the State, in accordance with article 6-II of the above-mentioned Order, a Representative of the State appointed by decree and, as the case may be, a number of staff representatives elected in accordance with the legal provisions in force.

LFB SA’s Board of Directors

Until the General Meeting of November 24th, 2016, in accordance with article 6 of French law #83-675 of July 26th, 1983 on the democratisation of the public sector, LFB SA’s Board of Director was comprised of 18 members divided between three colleges:

Qualified members

René ABATE – Managing Director, DELPHEN SARL

Christian BECHON** – Chairman and Chief Executive Officer, LFB SA, Chairman of the Board of Directors of LFB BIOMEDICAMENTS SA, Chairman of the Board of Directors of LFB BIOTECHNOLOGIES, Chairman of LFB GLOBAL PLASMA

Docteur Elisabeth HUBERT – Chair of HAD FRANCE SAS, Manager of ALIAGIS SARL

Manuela LEONE – Executive VP Operations, APTUIT SRL Verona, Italy (who resigned on May 2016)

Francis MER – Director of VIOHALCO SA, Belgium, Director of BORUSAN, Turkey

Jean-Marie ZACHARIE

French government representatives

Pierre ANGOT – Deputy Director of Chemistry, Materials and Eco-Industries, Department of Business, French Ministry of the Economy and Finance

Pascale AUGÉ – Chair of the Executive Board, INSERM TRANSFERT SA

François AUVIGNE – Inspector Gen. of Taxes, IFG, Ministry of the Economy and Finance

Thomas GOSSET – Deputy Director of Energy Holding in the French State Shareholding Agency

Jean Michel HEARD – Scientific Director for Bio-Health at the French Directorate-General for Research and Innovation

Staff representatives

Vincent DENOIS – Head of IT – LFB BIOMEDICAMENTS SA

Frédéric DHAINAUT – Head of Immunology and Applied Biochemistry – LFB BIOTECHNOLOGIES SASU

Nicolas HERMAN – Production Unit Manager – LFB BIOMEDICAMENTS SA

Marc LASCOMBES – Project Engineer – LFB BIOMEDICAMENTS SA

Hervé MARCILLY – Operations Quality Assurance Manager – R&D Quality Assurance – LFB BIOTECHNOLOGIES SASU

Dominique SAINT PICQ – Change Control Coordinator – LFB BIOMEDICAMENTS SA

 

The Board of Directors has now eight members:

Director representing the French government, appointed pursuant to the provisions of article 4 of the Order*:

  • Cédric GARCIN

4 Directors appointed at the General Meeting on the proposal of the French Government, chosen either for the technical, scientific or technological expertise, their knowledge of the local or regional aspects of the relevant activities, their knowledge of the public and private activities concerned by the company’s activity, or their capacity as representatives of consumers or users:

  • Pierre ANGOT – Deputy Director of Chemistry, Materials and Eco-Industries, Department of Business, French Ministry of the Economy and Finance
  • François AUVIGNE – Inspector Gen. of Taxes, IFG, Ministry of the Economy and Finance
  • Jean-Michel HEARD – Scientific Director for Bio-Health at the French Directorate-General for Research and Innovation
  • Pascale AUGÉ – Chair of the Executive Board, INSERM TRANSFERT SA

 

3 Directors elected as staff representatives:

  • Dominique SAINT PICQ – Change Control Coordinator – LFB BIOMEDICAMENTS SA
  • Wilhelmus STEVENS – Plasma proteins’ program Director – LFB BIOTECHNOLOGIES SA
  • Jérôme WACRENIER – IT industrial engineer – LFB BIOMEDICAMENTS SA

 

* https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000029391551&categorieLien=id

** By a letter from the Ministry of the Economy dated November 24th, 2016, Mr Christian BECHON was appointed acting Chairman & CEO of the Company pursuant to article 21 of the Order.